Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
about
Metabotropic glutamate receptors: from the workbench to the bedside.New small molecules for the treatment of Parkinson's disease.Exposure to glyphosate- and/or Mn/Zn-ethylene-bis-dithiocarbamate-containing pesticides leads to degeneration of γ-aminobutyric acid and dopamine neurons in Caenorhabditis elegans.Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.Adenosine A2A Receptor Gene Knockout Prevents l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia by Downregulation of Striatal GAD67 in 6-OHDA-Lesioned Parkinson's Mice.Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.Antidyskinetic Treatment with MTEP Affects Multiple Molecular Pathways in the Parkinsonian Striatum.Levodopa treatment and dendritic spine pathology.
P2860
Q30448778-420E0003-A011-4B1F-91EF-FE6CAC923825Q33636631-F74DC28C-60B4-4E09-AA3D-3E153924B2B2Q35785033-075EF6C2-CB9E-46E3-919D-39CEAE6E4C58Q35972575-F80FD153-C992-4B8E-B0BB-ED9A1CDC026CQ36422521-B1D86BAD-C73F-4AD2-AA6C-F5228EB77373Q37712460-744962CA-6458-494A-9ACD-4EE716E24A9FQ37782115-4A519FD9-75E2-4B88-B6E9-87536E73E649Q37974709-47DE690A-789B-4C5E-A8B6-6ACD3764B19EQ38056852-DB0D4FCA-C1BD-4A0E-B9F1-2DA0BBFCC07DQ38190016-84F22447-15D4-4D8B-A685-B7F2017003E5Q38660240-4FD8DFEF-C6A5-4477-8773-0AB72A22BDD9Q39324877-7F81020F-CCD6-4B3F-AD51-05443D9A2DEDQ42777922-CE9331D9-1267-4D5D-82F4-F7AAE7CE2256Q47137434-7CC6ECB0-8C3E-40ED-B806-227DE2CCE52CQ48113066-D74A6100-D88C-4FD0-86E2-DD40402E690D
P2860
Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metabotropic glutamate mGluR5 ...... hydroxydopamine-lesioned rats.
@en
Metabotropic glutamate mGluR5 ...... hydroxydopamine-lesioned rats.
@nl
type
label
Metabotropic glutamate mGluR5 ...... hydroxydopamine-lesioned rats.
@en
Metabotropic glutamate mGluR5 ...... hydroxydopamine-lesioned rats.
@nl
prefLabel
Metabotropic glutamate mGluR5 ...... hydroxydopamine-lesioned rats.
@en
Metabotropic glutamate mGluR5 ...... hydroxydopamine-lesioned rats.
@nl
P2860
P1433
P1476
Metabotropic glutamate mGluR5 ...... hydroxydopamine-lesioned rats.
@en
P2093
N Yamamoto
P2860
P304
P356
10.1016/J.NEUROSCIENCE.2009.07.060
P407
P577
2009-08-04T00:00:00Z